Trial Profile
A Phase I/II First in Human, Open Label, Multi-centre, Dose Escalation, Dose Finding, Safety and Tolerability Study of BVX20 administered intravenously in patients with Relapsed/Refractory CD20+ B cell Non Hodgkin's Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs BVX 20 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; First in man
- Sponsors Biocon
- 10 Jan 2020 Status changed from recruiting to discontinued.
- 04 Mar 2013 Planned end date 15 Jun 2014 added as reported by Clinical Trials Registry - India record.
- 04 Oct 2011 New trial record